Spruce Biosciences, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Spruce Biosciences, Inc. (SPRB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 409.85 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- Spruce Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 380.73K shares, a 54.37% increase year-over-year.
- Spruce Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 246.64K shares, a 98.81% decline year-over-year.
- Spruce Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 20.70M shares, a 6.47% increase year-over-year.
- Spruce Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 19.44M shares, a 423.82% increase year-over-year.
- Spruce Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 260.00K shares, a 4.27% increase from fiscal 2024.
- Spruce Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 249.35K shares, a 98.78% decline from fiscal 2023.
- Spruce Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 20.39M shares, a 215.41% increase from fiscal 2022.
- Spruce Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.47M shares, a 135.69% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 409.85K shares 10-Q · filed 2026-08-12 | |||||||
| 2026-03-31 | 380.73K shares 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | 260.00K shares 10-K · filed 2026-03-09 | |||||||
| 2025-09-30 | 236.08K shares 10-Q · filed 2025-11-10 | |||||||
| 2025-06-30 | 239.84K shares 10-Q · filed 2026-08-12 | |||||||
| 2025-03-31 | 246.64K shares 10-Q · filed 2026-05-13 | 18.50M shares 10-Q · filed 2025-05-06 | ||||||
| 2024-12-31 | 249.35K shares 10-K · filed 2026-03-09 | 18.77M shares 10-K · filed 2025-04-15 | ||||||
| 2024-09-30 | 275.44K shares 10-Q · filed 2025-11-10 | 20.72M shares 10-Q · filed 2024-11-12 | ||||||
| 2024-06-30 | 279.54K shares 10-Q · filed 2025-08-14 | 20.79M shares 10-Q · filed 2024-08-12 | ||||||
| 2024-03-31 | 20.70M shares 10-Q · filed 2025-05-06 | |||||||
| 2023-12-31 | 20.39M shares 10-K · filed 2025-04-15 | |||||||
| 2023-09-30 | 19.70M shares 10-Q · filed 2024-11-12 | |||||||
| 2023-06-30 | 19.96M shares 10-Q · filed 2024-08-12 | |||||||
| 2023-03-31 | 19.44M shares 10-Q · filed 2024-05-13 | |||||||
| 2022-12-31 | 6.47M shares 10-K · filed 2024-03-18 | |||||||
| 2022-09-30 | 4.95M shares 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | 4.52M shares 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | 3.71M shares 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | 2.74M shares 10-K · filed 2023-03-16 | |||||||
| 2021-09-30 | 2.56M shares 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | 2.65M shares 10-Q · filed 2022-08-10 | |||||||
| 2021-03-31 | 2.61M shares 10-Q · filed 2022-05-11 | |||||||
| 2020-12-31 | 2.30M shares 10-K · filed 2022-03-14 | |||||||
| 2020-09-30 | 17.94M shares 10-Q · filed 2020-11-18 | |||||||
| 2020-06-30 | 17.94M shares 10-Q · filed 2021-11-15 | 10.73M shares 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | 10.73M shares 10-Q · filed 2021-05-12 | |||||||
| 2019-12-31 | 5.19M shares 10-K · filed 2021-03-22 | |||||||
| 2019-09-30 | 5.00M shares 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |